Neuroreport (2009) 20:11616
Broeders M, Velseboer DC, de Bie R, Speelman JD, Muslimovic D, Post B, et al
Case Info GLP-1 Medications and NAION Vision Loss Lawsuit GLP-1 receptor agonists, widely prescribed to treat Type 2 diabetes and weight loss, have been linked to a higher risk of NAION
While very different to GLP-1 drugs, the history of the contraceptive pill holds many lessons for the new medication
In clinical trial settings, retatrutide is administered as a subcutaneous injection meaning it is injected into the fatty tissue just beneath the skin, rather than into a muscle or vein
Scientific References Retatrutide Phase 2 obesity trial GLP-1/GIP/glucagon triple agonist (Jastreboff et al., Eli Lilly)